ClinicalTrials.gov
ClinicalTrials.gov Menu

Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00677482
Recruitment Status : Unknown
Verified May 2015 by Deepali Kumar, University of Alberta.
Recruitment status was:  Active, not recruiting
First Posted : May 14, 2008
Last Update Posted : May 27, 2015
Sponsor:
Information provided by (Responsible Party):
Deepali Kumar, University of Alberta

Brief Summary:
Cytomegalovirus (CMV) is the most common viral infection in patients who have undergone a transplant.Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. The purpose of this study is to assess how the virus interacts with the patient's immune system, so that in the future it may be possible to develop better ways to prevent and treat the virus infection.

Condition or disease
Transplant

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cytomegalovirus (CMV) microRNA Expression in Vivo and Immune Evasion Correlates
Study Start Date : April 2008
Estimated Primary Completion Date : July 2016
Estimated Study Completion Date : December 2016

Group/Cohort
1
Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Solid organ tranplant recipients with both asymptomatic CMV viremia and symptomatic CMV disease are eligible for inclusion in the study. This include liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.
Criteria

Inclusion Criteria:

Male or female patients who fulfill the following criteria are eligible for inclusion:

  • Age >=18 years
  • Solid Organ Transplant Recipients
  • Documented CMV disease or asymptomatic CMV viremia

Exclusion Criteria:

  • Unable to comply with protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00677482


Locations
Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G-2E1
Sponsors and Collaborators
University of Alberta
Investigators
Principal Investigator: Atul Humar, MD University of Alberta

Publications:
Responsible Party: Deepali Kumar, Assistant Professor of Medicine, University of Alberta
ClinicalTrials.gov Identifier: NCT00677482     History of Changes
Other Study ID Numbers: 7304
First Posted: May 14, 2008    Key Record Dates
Last Update Posted: May 27, 2015
Last Verified: May 2015

Keywords provided by Deepali Kumar, University of Alberta:
liver transplant
lung transplant
kidney transplant
heart transplant
CMV microRNA